Quantinno Capital Management Increases Stake in Qiagen

Quantinno Capital Management LP has increased its shares in Qiagen (NYSE:QGEN - Free Report) by 31.2% during the third quarter, as reported in their recent filing with the SEC. Following the purchase of an additional 18,716 shares, the fund now holds 78,707 shares of Qiagen's stock, which have a total value of approximately $3,562,000.

• Strategic Buy Lights Up This Biotech Stock: Time to Invest?

Additionally, other hedge funds have also made changes to their positions in Qiagen. For instance, GAMMA Investing LLC has significantly increased its share in Qiagen by 806.5% during the third quarter, now owning 562 shares valued at $26,000 after acquiring 500 shares in that period. Toronto Dominion Bank has taken a new position worth $27,000 in Qiagen in the second quarter. Moreover, Massmutual Trust Co. FSB ADV has increased its holdings by 39.8% during the third quarter, owning 853 shares valued at $39,000 after buying 243 additional shares. CWM LLC has raised its position by 12.0% in the second quarter, bringing its total to 2,505 shares valued at $103,000 after a purchase of 269 shares. Finally, Headlands Technologies LLC has elevated its stake in Qiagen by 396.6% in the second quarter, now having 2,741 shares worth $113,000 after adding 2,189 shares to its holdings. As a result, institutional investors and hedge funds now hold about 70% of the company's stock.

Current Performance of Qiagen Stock

On Monday, Qiagen's stock opened at $43.42. The company maintains a 50-day moving average of $43.09 and a two-hundred-day moving average of $43.64. Financial metrics indicate a quick ratio of 1.89, a current ratio of 2.17, and a debt-to-equity ratio of 0.39. Over the past twelve months, Qiagen’s stock has reached a low of $39.03 and a high of $47.44, putting the company's market cap at approximately $9.91 billion. The price-to-earnings ratio stands at 111.33, with a PEG ratio of 3.39 and a beta of 0.35.

Analysts' Predictions for Growth

Learn More About Qiagen

About Qiagen

(Free Report)

QIAGEN N.V. specializes in providing solutions that convert biological samples into molecular insights on a global scale. The company offers products for sample technology, including kits for the stabilization and purification of biological samples, tools for genomics processing, and technologies for nucleic acid purification.

Further Reading

• Five stocks we like better than Qiagen
• Investing in High Beta Stocks for Maximum Returns
• Guidewire Software: A Promised Buying Opportunity
• Small Cap Stocks: Investment Guide
• Recent Stock Upgrades and Their Impact
• Finding 52-Week Stock Highs and Lows
• Undervalued Fast-Growing Companies

Discover Other Hedge Fund Holdings in Qiagen.

Note: This news update is generated using automated technology to provide efficient and timely information. All data has been reviewed by a dedicated editorial team before publication.

Investment Consideration

Before making any investment in Qiagen, investors should do their own research and evaluation. Current analyst ratings indicate a "Moderate Buy" for Qiagen, though top analysts have highlighted five other stocks they believe to be more promising right now.

Click here to explore these additional stock recommendations.

Qiagen, Investments, HedgeFunds